Informative value of procalcitonin in determining the nature of an inflammatory response in rheumatology
https://doi.org/10.14412/1996-7012-2017-1-66-71
Abstract
The paper reviews the literature regarding the use of procalcitonin (PCT) as a marker providing a differential diagnosis between diffuse connective tissue diseases, active systemic vasculitis, and manifestations of systemic bacterial infection. The discriminatory significance of PCT in most cases varies from 0.1 to 0.5 ng/ml. At the same time it has been found that the level of PCT in some forms of systemic vasculitis (adultonset Still's disease, macrophage activation syndrome) may correspond to that in systemic bacterial infections. In this connection, the role of PCT should not be absolutized; it may serve only as a great help using the current methods for X-ray, microbiological, and laboratory investigation. The diagnostic value of PCT in these clinical situations can be enhanced by the combined determination of its blood levels and the severity of organ dysfunction in accordance with the Sepsis-related Organ Failure Assessment (SOFA) scale.
About the Authors
O. V. Teplyakova
Ural State Medical University, Ministry of Health of Russia
Russian Federation
3, Repin St., Yekaterinburg 620028
Russian Federation
3, Repin St., Yekaterinburg 620028
V. A. Rudnov
Ural State Medical University, Ministry of Health of Russia
City Clinical Hospital Forty
Russian Federation
Russian Federation
3, Repin St., Yekaterinburg 620028
189, Volgogradskaya St., Yekaterinburg 620102
References
1. Shi Y, Peng YM, Hu XY, Wang Y. The utility of initial procalcitonin and procalcitonin clearance for prediction of bacterial infection and outcome in critically ill patients with autoimmune diseases: a prospective observational study. BMC Anesthesiol. 2015 Oct 7;15:137. doi: 10.1186/s12871-015-0122-9.
2. Muller B, Becker K. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly. 2001 Oct 20;131 (41-42):595-602.
3. Muller B, White JC, Nylen E, et al. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001 Jan;86(1): 396-404.
4. Becker KL, Nylen ES, White JC, et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. Endocrinol Metab. 2004 Apr;89(4):1512-25.
5. Meisner M. Procalcitonin – a new, innovative infection parameter. Berlin: Brahms Diagnostica; 1996. P. 3-41.
6. Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patienys with sepsis and infection. Lancet. 1993 Feb 27;341(8844):515-8.
7. Eberhard OK, Haubitz M, Brunkhorst FM, et al. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody- associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997 Jul;40(7):1250-6.
8. Wu JY, Lee SH, Shen CJ, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012 Sep;64(9):3034-42. doi: 10.1002/art.34512.
9. Lanoix JP, Bourgeois AM, Schmidt J, et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus. 2011 Feb;20(2):125-30. doi: 10.1177/0961203310378862. Epub 2010 Oct 11.
10. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013 Feb;41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.
11. Тарасова ГМ, Белов БС, Александрова ЕН, Новиков АА. Прокальцитониновый тест при ревматических заболеваниях. Научно-практическая ревматология. 2014;52(4):387- 92. [Tarasova GM, Belov BS, Aleksandrova EN, Novikov AA. Procalcitonin test in rheumatic diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4):387-92. (In Russ.)]. doi: 10.14412/1995-4484-2014-387-392.
12. Herrmann K, Schinke S, Csernok E, et al. Diagnostic Value of Procalcitonin in ANCAAssociated Vasculitis (AAV) to Differentiate Between Disease Activity, Infection and Drug Hypersensitivity. Open Rheumatol J. 2015 Oct 9;9:71-6. doi: 10.2174/1874312901409010071. eCollection 2015.
13. Lin CH, Hsieh SC, Keng LT, et al. Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and C-Reactive Protein in Febrile Patients with Autoimmune Diseases. PLoS One. 2016 Apr 20;11(4):e0153938. doi: 10.1371/journal.pone.0153938. eCollection 2016.
14. Лапин СВ, Маслянский АЛ, Лазарева НМ и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных с аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика. 2013;(1):28-33. [Lapin SV, Maslyanskii AL, Lazareva NM, et al. The value of quantitative determination of procalcitonin for the diagnosis of septic complications in patients with autoimmune rheumatic diseases. Klinicheskaya laboratornaya diagnostika. 2013;(1):28-33. (In Russ.)].
15. Vincent JL, Moreno R, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996 Jul;22(7):707-10.
16. Scirе CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006 Mar-Apr;24(2):123-8.
17. Serio I, Arnaud L, Mathian A, et al. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clin Rheumatol. 2014 Sep; 33(9):1209-15. doi: 10.1007/s10067-014-2738-4. Epub 2014 Jul 27.
18. Okada Y, Minakami H, Tomomasa T, et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect. 2004 Feb;48(2):199-205.
19. Moosing F, Csernok E, Reinhold-Keller E, et al. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol. 1998 Aug;25(8):1531-3.
20. Morath C, Sis J, Haensch GM, et al. Procalcitonin as marker of infection in patients with Goodpasture's syndrome is misleading. Nephrol Dial Transplant. 2007 Sep;22(9):2701-4. Epub 2007 Jun 7.
21. Rosario C, Zandman-Goddard G, Meyron-Holtz E, et al. The Hyperferritinemic Syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013 Aug 22;11:185. doi: 10.1186/1741-7015-11-185.
22. Nisten MW, Olingap P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28:458-61.
23. Kettelhack C, Hohenberger P, Schulze G, et al. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med. 2000 Apr;28(4):1040-6.
24. Zeni F, Vialon A, Tardy B, et al. Serum procalcitonin in sepsis: relation to severity and cytocines (TNF, IL-6, IL-8). 34th Interscience Conference of Antimicrobial Agents and Chemotherapy, 4–7 October 1994, Orlando.
25. Kaieda S, Yoshida N, Yamashita F, et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis. Mod Rheumatol. 2015;25(6):962-6. doi: 10.3109/14397595.2013.844402. Epub 2013 Oct 21.
26. Uemura M, Huynh R, Kuo A, et al. Hemophagocytic Lymphohistiocytosis Complicating T- Cell Lymphoma in a Patient with HIV Infection. Case Rep Hematol. 2013;2013:687260. doi: 10.1155/2013/687260. Epub 2013 Aug 31.
27. Muller C, Manhardt LB, Willaschek C, et al. Beta-Blocker Therapy and Hemophagocytic Lymphohistiocytosis: A Case Report. Cardiol Res Pract. 2010;2010:912757. doi: 10.4061/2010/912757. Epub 2010 Jun 20.
28. Захарова АЮ, Мутовина ЗЮ, Гордеев АВ, Шестакова ИН. Трудности диагностики гемофагоцитарного синдрома у пациентки с болезнью Стилла взрослых. Терапевтический архив. 2015;(5): 84-9. [Zakharova AYu, Mutovina ZYu, Gordeev AV, Shestakova IN. Difficulties in the diagnosis of hemophagocytic syndrome in a patient with adult Still's disease. Terapevticheskii arkhiv. 2015;(5):84-9. (In Russ.)].
29. Сhen DY, Chen YM, Ho WL, et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis. 2009 Jun;68(6):1074-5. doi: 10.1136/ard.2008.098335.
Review
For citations:
Teplyakova OV, Rudnov VA. Informative value of procalcitonin in determining the nature of an inflammatory response in rheumatology. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2017;11(1):66-71. (In Russ.) https://doi.org/10.14412/1996-7012-2017-1-66-71
Views:
717
Email this article 